RxDoctor Payments Data

Donald Balacuit, DO

Family Medicine · Monrovia, CANPI 1598737116

Payments from drug & device makers

$280in general payments, 2019–2025

Across 12 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$51
  • Teva Pharmaceuticals USA, Inc.$41
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$39
  • Novo Nordisk$25
  • Avanir Pharmaceuticals, Inc.$24
  • Amgen$24
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$280100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$280 in reported general payments places this provider in the 50th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$131,786
Medicare patients
210
Services billed
1,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$48,909
XareltoRivaroxaban51$18,944
JanuviaSitagliptin Phosphate27$15,731
JardianceEmpagliflozin27$13,032
OzempicSemaglutide13$12,167
TradjentaLinagliptin22$11,161
NuedextaDextromethorphan Hbr/Quinidine14$7,779
InvokanaCanagliflozin13$7,655
Divalproex Sodium50$3,923
SynjardyEmpagliflozin/Metformin Hcl12$3,665
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$3,275
Atorvastatin Calcium293$2,949
Levothyroxine Sodium156$2,397
Lacosamide23$2,369
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen135$2,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$12,16713 claims
Avanir Pharmaceuticals, Inc.Nuedexta$24$7,77914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 10,533 family medicine providers in California.

Other family medicine in Monrovia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →